Cancer Moonshot℠ – Funding Opportunities
The funding opportunity announcements (FOAs) listed below highlight research initiatives that align with the efforts of the Cancer Moonshot. They may be supported with existing funds or with the 21st Century Cures funding.
Please note that all publications and data resulting from Cancer Moonshot funded initiatives will be required to be immediately accessible. For more information, see the Cancer Moonshot Public Access and Data Sharing Policy.
|BRP Recommendation||Title||Announcement Number||Receipt Date|
|Therapeutic Target Identification to Overcome Resistance||Notice of Special Interest: Administrative Supplements to Support Collaborations with the Drug Resistance and Sensitivity Network (DRSN)||NOT-CA-19-032||07/01/2019|
|New Enabling Technologies||Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the PDX Development and Trial Centers Research Network (PDXNet) (Admin Supp Clinical Trial Not Allowed)||PA-19-174||03/28/2019|
|Cancer Immunotherapy Translational Science Network||Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01)||PAR-17-245||Multiple|
|Cancer Immunotherapy Translational Science Network||Collaborative Research Projects to Enhance Applicability of Mammalian Models for Translational Research (Collaborative R01)||PAR-17-244||Multiple|
|Cancer Immunotherapy Translational Science Network||Metabolic Reprogramming to Improve Immunotherapy (R21)||PAR-16-229||Multiple|
|Cancer Immunotherapy Translational Science Network||Metabolic Reprogramming to Improve Immunotherapy (R01)||PAR-16-228||Multiple|
|Drivers of Childhood Cancers||Gene Fusions in Pediatric Sarcomas (R21)||PA-16-252||Multiple|
|Drivers of Childhood Cancers||Gene Fusions in Pediatric Sarcomas (R01)||PA-16-251||Multiple|
|Generation of Human Tumor Atlases||Emerging Questions in Cancer Systems Biology (U01)||PAR-16-131||Multiple|
|Cancer Immunotherapy Translational Science Network||Advancing Cancer Immunotherapy by Mitigating Immune-Related Adverse Events (irAE) (U01 Clinical Trial Not Allowed)||RFA-CA-19-044||04/25/2019|
|Cancer Immunotherapy Translational Science Network||Notice of Special Interest: Administrative Supplements for Activities to Promote Human Immune-Representing Oncology Models||NOT-CA-19-028||06/03/2019|
|Symptom Management Research||Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors||RFA-CA-19-033||01/03/2020|